AstraZeneca Toprol Patents Are Invalid, Finds Federal Judge

A St. Louis federal court finds both of AstraZeneca’s patents protecting the beta blocker invalid due to double patenting and unenforceable because of AstraZeneca’s “inequitable conduct” with the patent office.